Skip to content

Home-Based Heat Therapy in Spinal Cord Injury to Improve Cardiovascular Health

Home-Based Passive Heat Therapy-Towards a Scalable Intervention to Improve Cardiovascular Health in Persons With Spinal Cord Injury

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07317843
Acronym
IIS_SCIDoD
Enrollment
48
Registered
2026-01-05
Start date
2026-03-24
Completion date
2031-07-01
Last updated
2026-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

SCI - Spinal Cord Injury

Keywords

SCI, heat therapy, heat stress, passive heat, vascular function

Brief summary

The study is designed to investigate the effects of passive heat therapy on blood vessel health in 40 people (48 enrolled with attrition rate of 20%). Following an extensive set of vascular function tests, participants will engage in either a passive heat therapy intervention for 60 minutes, 4 times a week for 8 weeks, or a placebo intervention at a lower temperature. Seven of the 8 weeks of intervention will occur in the home setting. Vascular function tests will be repeated after the 8 weeks to determine if chronic passive heat stress improved vascular health.

Detailed description

The experimental arm (HEAT) participants undergo an 8-week intervention with 4 weekly passive heat therapy sessions. The aim of each session is to raise the participants' core temperature by at least 1°C by resting under heating blankets set at approximately 42°C. The control arm (SHAM) participants undergo the same procedure as above except the temperature setting of the blankets is lower at approximately 34°C. Screening, baseline assessments and the first 4 sessions will be conducted in the investigator's SCI lab to familiarize the participant with how to apply the heating blankets and ensure safety. After the 4th session, participants will receive a heating blanket for use at home in the remaining 7 intervention weeks. Cardiac MRI and peripheral vascular assessments are performed at baseline and within two weeks after completing the intervention. Weekly sessions (4x per week) in weeks 2 to 8 will be performed at home and secure VA-approved online video conferencing software will be used by study staff to remotely supervise the sessions and collect data.

Interventions

OTHERHEAT - Passive Heat Therapy

Participant rests under a heated blanket until the core body temperature has increased at minimum 1 degree Celsius. This usually takes approximately 1 hour. The intervention is performed 4 times a week for a total of 8 weeks.

OTHERSham (No Treatment)

The SHAM intervention participant will rest under a heated blanket that is not set to the degree that the HEAT arm receives. There is no increase of core body temperature.

Sponsors

The University of Texas Health Science Center at San Antonio
Lead SponsorOTHER
Congressionally Directed Medical Research Programs
CollaboratorFED

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

1. Participant demonstrates understanding of the study and has provided an appropriately signed and dated informed consent. 2. Participants will be male or female, 18-60 years of age, at the time of Visit 0. 3. Female participants must be non-lactating. Female patients are eligible only if they have a negative pregnancy test throughout the study period (or are postmenopausal). Postmenopausal women taking hormone replacement will be included if they have been on a stable dose for =6 months. 4. Stable SCI (AIS A or B) of longer than 1-year duration. 5. Use of medications for clinical management of medical problems directly related to SCI is not considered an exclusion criterion. Status such as detrusor instability, muscle spasms, and other common SCI problems (other than those that could alter vascular responsiveness) may be allowed for those SCI participants who have been on stable doses for =6 months. Results from participants taking such medications will be analyzed to determine possible medication-related differences from those on no medications.

Exclusion criteria

1. Participants who smoke, or: 2. Uses daily administration of anti-inflammatory medications (stable doses of NSAIDs or statins are acceptable; steroids are exclusionary) 3. Uses daily administration of vasoactive medications (e.g., alpha antagonists or agonists or phosphodiesterase inhibitors). 4. Has a current pressure ulcer or skin breakdown. 5. Has an active, uncontrolled, autoimmune or inflammatory disorder 6. Has no history of or current alcohol or substance use disorder 7. Has a history of heat related illness (e.g., heat stroke) 8. Has a history of any illness that, in the opinion of the study investigator, might confound the results of the study or poses an additional risk to the participant by their participation in the study. This includes, but is not limited to, a clinically relevant medical or surgical history. 9. Is unlikely to cooperate with the requirements of the study.

Design outcomes

Primary

MeasureTime frameDescription
Laser Doppler Flowmetry (LDF)From baseline to end of treatment at 8 weeksMeasure of skin blood flow due to local skin heating

Secondary

MeasureTime frameDescription
Endothelial Peripheral Arterial Tone (EndoPAT)Baseline to end of treatment at 8 weeksMeasures the changes in finger pulsatile arterial volume
Venous Occlusion Plethysmography (VOP)From baseline to end of treatment at 8 weeksLimb blood flow measurement
Cardiac MRIBaseline to end of treatment at 8 weeksMeasures stiffness of the aorta

Countries

United States

Contacts

CONTACTMichelle Trbovich, MD
michelle.trbovich@va.gov210-617-5300
CONTACTDean L Kellogg, Jr, MD, PhD
kelloggd@uthscsa.edu210-617-5300
PRINCIPAL_INVESTIGATORMichelle Trbovich, MD

The University of Texas Health Science Center at San Antonio

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 6, 2026